Latham & Watkins represented the underwriters in the offering.Travere Therapeutics, Inc. executed its offering of US$275 million aggregate principal amount of 2.25% convertible senior notes due 2029. The…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
